Pnina Fishman - Can Fite CEO, Director
| CANF Stock | USD 2.10 0.05 2.44% |
CEO
Dr. Pnina Fishman serves as Chief Executive Officer and served on our Board of Directors since September 2005. She has also served as the Chief Executive Officer of OphthaliX from November 21, 2011 through December 31, 2012. Dr. Fishman is the scientific founder of CanFite and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center, Israel. Dr. Fishman has authored or coauthored over 150 publications and presented the findings of her research at many major scientific meetings. Her past managerial experience included seven years as Chief Executive Officer of Mor Research Application, the technology transfer arm of Clalit Health Services, the largest healthcare provider in Israel. Mor Research Application was also the first clinical research organization in Israel. Dr. Fishman currently also serves as a member of the Board of Directors of F.D Consulting Ltd., Ultratrend Ltd., EyeFite Ltd. and OphthaliX Inc since 1994.
| Age | 76 |
| Tenure | 30 years |
| Professional Marks | Ph.D |
| Address | 26 Ben Gurion Street, Ramat Gan, Israel, 5257346 |
| Phone | 972 3 924 1114 |
| Web | https://www.canfite.com |
Can Fite Management Efficiency
The company has return on total asset (ROA) of (0.5746) % which means that it has lost $0.5746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5762) %, meaning that it created substantial loss on money invested by shareholders. Can Fite's management efficiency ratios could be used to measure how well Can Fite manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.8. The current Return On Capital Employed is estimated to decrease to -1.08. At this time, Can Fite's Other Current Assets are most likely to increase significantly in the upcoming years. The Can Fite's current Total Current Assets is estimated to increase to about 10.3 M, while Non Currrent Assets Other are forecasted to increase to (107.7 K).Similar Executives
| Found 12 records | CEO Age | ||
| Michael Brigham | ImmuCell | 63 | |
| Ofer CPA | Evogene | 58 | |
| PharmD PharmD | Cingulate | 49 | |
| Dror Bashan | Protalix Biotherapeutics | 57 | |
| Cary MBA | Adial Pharmaceuticals | 63 | |
| Yehiel Tal | Collplant Biotechnologies | 72 | |
| Thomas MBA | Transcode Therapeutics | 72 | |
| Shane PharmD | Cingulate | 49 | |
| CFA III | Checkpoint Therapeutics | 48 | |
| Nadav Esq | Oramed Pharmaceuticals | 50 | |
| FOCIS MD | Candel Therapeutics | 63 | |
| Anat CohenDayag | Compugen | 57 | |
Management Performance
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.57 |
Can Fite Biopharma Leadership Team
Elected by the shareholders, the Can Fite's board of directors comprises two types of representatives: Can Fite inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Can. The board's role is to monitor Can Fite's management team and ensure that shareholders' interests are well served. Can Fite's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Can Fite's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Motti Farbstein, Chief Operating and Financial Officer and Principal Accounting Officer | ||
| Sari Fishman, Vice Development | ||
| Ilan Cohn, CoFounder Chairman | ||
| FACP FACR, Clinical Advisor | ||
| MD FACP, Member Officer | ||
| Pnina Fishman, CEO, Director |
Can Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Can Fite a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.57 | ||||
| Operating Margin | (12.96) % | ||||
| Current Valuation | 8.25 M | ||||
| Shares Outstanding | 6.1 M | ||||
| Shares Owned By Institutions | 11.65 % | ||||
| Number Of Shares Shorted | 135.59 K | ||||
| Price To Earning | (3.41) X | ||||
| Price To Book | 5.19 X | ||||
| Price To Sales | 18.82 X |
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Quarterly Revenue Growth (0.19) | Return On Assets (0.57) | Return On Equity (1.58) |
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.